Intravenous ketamine or esketamine given at the time of cesarean delivery reduced risk for postpartum depression; predictive models are needed to determine which women are most likely to benefit from this intervention.
The FDA approves zuranolone, a new option for the treatment of PPD, a rapidly acting antidepressant with a good safety profile.
In women with severe postpartum depression, zuranolone was associated with improvements in depression beginning at day 3. FDA to make a decision next week.
Women with medical, psychiatric, and obstetric risk factors should be closely followed within pregnancy and the postpartum.
In this postmarketing surveillance data analysis, excessive sedation and loss of consciousness when receiving brexanolone occurred at lower rates than previously reported in clinical trials.
This hotline will offer a range of support, including brief interventions, referrals to both community-based and telehealth providers as needed.
Addressing sleep problems may be an important component of suicide prevention efforts, as improving sleep quality and duration may help to reduce the risk of suicide in perinatal population.
This preliminary study suggests that web-based interventions with coaching are feasible, acceptable, and potentially effective treatment options for women with mild to moderate postpartum depression and/or anxiety.
In this randomized controlled trial, a CBT-based workshop for women with PPD led to clinically meaningful reductions in depression and anxiety.
Postpartum psychosis is the most severe form of postpartum psychiatric illness. What are the signs and symptoms?
